Results 181 to 190 of about 5,563 (240)

Erratum: Human endoglin-CD3 bispecific T cell engager antibody induces anti-tumor effect in vivo. [PDF]

Theranostics
Zhong L, Shi W, Gan L, Liu X, Huo Y, Wu P, Zhang Z, Wu T, Peng H, Huang Y, Zhao Y, Yuan Y, Deng Z, Tang H.   +13 more
europepmc   +1 more source

Targeting IL13Rα2 in melanoma with a bispecific T-cell engager: expression profiling and preclinical evaluation. [PDF]

J Immunother Cancer
Zhao S, Chen Y, Bhojnagarwala PS, Livingston C, Jose J, Gao Y, Park DH, Herlyn M, Weiner DB.   +8 more
europepmc   +1 more source

A measles virus encoding a CD19/CD3 bispecific T cell engager shows enhanced preclinical anti-BCP-ALL efficacy without significant toxicity. [PDF]

Mol Ther Oncol
Heinze S, Stadler GL, Zhang Y, Engeland CE, Barth TFE, Heidbuechel JPW, Meyer LH, Mühlebach MD, Debatin KM, Dorneburg C, Beltinger C.   +10 more
europepmc   +1 more source

Solution structure and synaptic analyses reveal determinants of bispecific T cell engager potency. [PDF]

Proc Natl Acad Sci U S A
Leithner A, Staufer O, Mitra T, Liberta F, Valvo S, Kutuzov M, Dada H, Spaeth J, Zhou W, Schiele F, Reindl S, Nar H, Hoerer S, Crames M, Comeau S, Young D, Low S, Jenkins E, Davis SJ, Klenerman D, Nixon A, Pefaur N, Wyatt D, Dushek O, Kasturirangan S, Dustin ML.   +25 more
europepmc   +1 more source

Virus envelope glycoprotein targeting bispecific T cell engager protects mice from lethal severe fever with thrombocytopenia virus infection. [PDF]

Cell Rep Med
Peng X, Wang W, Liang Y, Jian Y, Wei Q, Yang T, Wang C, Yin X, Du M, Shang H, Liu R, Wang X, Shang X, Gong N, Xu Y, Wang C, Cui N, Zhang L, Guo Y, Liu W, Zhang H, Li H.   +21 more
europepmc   +1 more source

Targeting mutated KRAS by HLA-A*02:01 restricted anti-KRAS TCR-mimic CAR and bispecific T cell engager. [PDF]

J Mol Med (Berl)
Ebrahimi S, Lohnes BJ, Khan SA, Peipp M, Bockamp E, Klein C, Abken H, Wölfel C, Theobald M, Hartwig UF.   +9 more
europepmc   +1 more source

A Novel B7-H4xCD3 Bispecific T-cell Engager (PF-07260437) Synergizes with Breast Cancer Standard of Care and Immune Checkpoint Therapies. [PDF]

Mol Cancer Ther
Abayasiriwardana K, Wu L, Laklai H, Nocula-Lugowska M, Tchistiakova L, Narula J, Jackson-Fisher A, Golas J, Lam MH, Grinstein V, Kang JW, Kearney JC, Hosselet C, Upeslacis E, Lemon L, Zhang Y, Ji C, Buetow BS, Finkelstein MB, Marshall N, Bisulco S, Rosfjord E, Mathur D, Athanacio J, Thomas A, Trageser A, Fernandez D, Jiang ZK, Ram S, Cabral E, Manzuk L, Maresca K, Giddabasappa A, Lees C, Hooper AT, Sapra P, Chintharlapalli S.   +36 more
europepmc   +1 more source

A ROR1 targeted bispecific T cell engager shows high potency in the pre-clinical model of triple negative breast cancer. [PDF]

Breast Cancer Res
Wang F, Li W, Han G, Xie J, Bai X.
europepmc   +1 more source

Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase I Study. [PDF]

J Clin Oncol
Stein MN, Vinceneux A, Robbrecht D, Doger B, Autio KA, Schweizer MT, Calvo E, Medina L, Van Dongen M, Deville JL, Bernard-Tessier A, Ghosh D, Shotts K, Shen F, Jaiprasart P, Chaudhary R, Wu S, Cartee L, Schnepp R, Gaut D, Lauring J, Wang SC, Villalobos VM, Baldini C.   +23 more
europepmc   +1 more source

A novel bispecific T-cell engager using the ligand-target csGRP78 against acute myeloid leukemia. [PDF]

Cell Mol Life Sci
Zeng X, Zhang H, Guo J, Yang D, Zhu Y, Liu N, Tang J, Liu T, Zhao X.   +8 more
europepmc   +1 more source